| Bioactivity | Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor[1]. |
| In Vivo | Tixagevimab 可以与 Cilgavimab 组合，形成 AZD7442，AZD7442（2，4 或 16 mg/kg，静脉注射）在感染 G61 菌株的仓鼠以及在感染了 Omicron 变种的仓鼠中，可以导致肺部感染滴度和病毒 RNA 水平呈剂量依赖性下降，且与 2 mg/kg 剂量的动物相比，16 mg/kg 剂量的感染滴度显著降低[2]。 |
| Name | Tixagevimab |
| CAS | 2420564-02-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jinhui Dong, et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat Microbiol. 2021 Oct;6(10):1233-1244. [2]. Jean-Sélim DRIOUICH, et al. Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster model. |